CG Oncology
guidance on unresponsive risks development regulatory pathway to approval | CG Oncology
Company
Deck Type
IPO
Sector
Industry
Deck date
March 2024
Slide
14 of 45
Related slides by other companies
Dare Bioscience
Investor Presentation
February 2023
dare regulatory strategy following clinical development dar intends to leverage the existing safety and efficacy data on the active ingredients in dare estradiol and progesterone to utilize the food and drug administration pathway to obtain marketing approval of dare in the dar intends to seek approval of dare for the treatment of moderate to severe due to menopause in women with intact uteri based on communications with the and the topline data from the dare phase study dar believes approval of dare for that indication is achievable via the pathway supported by a single placebo controlled phase clinical trial of dare and a scientifically justified bridge via a relative trial between dare and the selected listed estradiol and progesterone drugs ongoing activities to support progressing directly into a single phase study to support registration include manufacturing and non clinical studies to support the submission and the planned opening phase study dare strategy | Dare Bioscience
Certara
Investor Day
December 2021
drug approvals using | Certara
AbCellera
Investor Conference
May 2022
forward integration to accelerate drug development meal | AbCellera
Ocuphire Pharma
Investor Day
January 2022
what important guidance physician patients | Ocuphire Pharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io